Published in J Virol on June 01, 1992
In vivo control of NF-kappa B activation by I kappa B alpha. EMBO J (1993) 3.11
I kappa B epsilon, a novel member of the I kappa B family, controls RelA and cRel NF-kappa B activity. EMBO J (1997) 2.26
IkappaB alpha is a target for the mitogen-activated 90 kDa ribosomal S6 kinase. EMBO J (1997) 1.91
The NF-kappa B precursor p105 and the proto-oncogene product Bcl-3 are I kappa B molecules and control nuclear translocation of NF-kappa B. EMBO J (1993) 1.90
NF-kappa B p100 (Lyt-10) is a component of H2TF1 and can function as an I kappa B-like molecule. Mol Cell Biol (1993) 1.79
Kappa B site-dependent activation of the interleukin-2 receptor alpha-chain gene promoter by human c-Rel. Mol Cell Biol (1992) 1.52
Hormone-regulated v-rel estrogen receptor fusion protein: reversible induction of cell transformation and cellular gene expression. EMBO J (1992) 1.30
Interaction of the v-Rel oncoprotein with cellular transcription factor Sp1. J Virol (1994) 1.12
The v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice. EMBO J (1996) 1.12
Differential pp40I kappa B-beta inhibition of DNA binding by rel proteins. Mol Cell Biol (1993) 1.00
v-rel induces expression of three avian immunoregulatory surface receptors more efficiently than c-rel. J Virol (1994) 0.99
Identification of a C/EBP-Rel complex in avian lymphoid cells. Mol Cell Biol (1994) 0.96
Expression of constitutively active IkappaB beta in T cells of transgenic mice: persistent NF-kappaB activity is required for T-cell immune responses. Mol Cell Biol (1998) 0.95
Avian I kappa B alpha is transcriptionally induced by c-Rel and v-Rel with different kinetics. J Virol (1995) 0.94
NF-kappa B p100 is one of the high-molecular-weight proteins complexed with the v-Rel oncoprotein in transformed chicken spleen cells. J Virol (1993) 0.92
In vivo evolution of c-rel oncogenic potential. J Virol (1994) 0.92
Mapping of a serine-rich domain essential for the transcriptional, antiapoptotic, and transforming activities of the v-Rel oncoprotein. Mol Cell Biol (1999) 0.91
The relocalization of v-Rel from the nucleus to the cytoplasm coincides with induction of expression of Ikba and nfkb1 and stabilization of I kappa B-alpha. J Virol (1995) 0.88
Downregulation of MHC class I expression due to interference with p105-NF kappa B1 processing by Ad12E1A. EMBO J (1995) 0.86
Transformation of avian fibroblasts overexpressing the c-rel proto-oncogene and a variant of c-rel lacking 40 C-terminal amino acids. J Virol (1994) 0.86
GAL4-I kappa B alpha and GAL4-I kappa B gamma activate transcription by different mechanisms. Nucleic Acids Res (1993) 0.83
Mutations in the DNA-binding and dimerization domains of v-Rel are responsible for altered kappa B DNA-binding complexes in transformed cells. J Virol (1995) 0.82
Retroviral transformation in vitro of chicken T cells expressing either alpha/beta or gamma/delta T cell receptors by reticuloendotheliosis virus strain T. J Exp Med (1993) 0.80
Heterologous C-terminal sequences disrupt transcriptional activation and oncogenesis by p59v-rel. J Virol (1993) 0.80
Identification of a rel-related protein in the nucleus during the S phase of the cell cycle. Mol Cell Biol (1993) 0.80
Mutational analysis of the v-Rel dimerization interface reveals a critical role for v-Rel homodimers in transformation. J Virol (2002) 0.79
Interaction of the v-Rel oncoprotein with NF-kappaB and IkappaB proteins: heterodimers of a transformation-defective v-Rel mutant and NF-2 are functional in vitro and in vivo. Mol Cell Biol (1996) 0.78
Nuclear Factor kappa B is central to Marek's disease herpesvirus induced neoplastic transformation of CD30 expressing lymphocytes in-vivo. BMC Syst Biol (2012) 0.78
Constitutive and inducible kappa B binding activities in the cytosol of v-Rel-transformed lymphoid cells. J Virol (1995) 0.76
Transcription factor regulation and cytokine expression following in vitro infection of primary chicken cell culture with low pathogenic avian influenza virus. Virol J (2013) 0.75
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
Peptide mapping by limited proteolysis in sodium dodecyl sulfate and analysis by gel electrophoresis. J Biol Chem (1977) 72.51
Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell (1986) 42.45
I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science (1988) 16.40
Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell (1986) 15.30
The DNA binding subunit of NF-kappa B is identical to factor KBF1 and homologous to the rel oncogene product. Cell (1990) 9.37
Cloning of the p50 DNA binding subunit of NF-kappa B: homology to rel and dorsal. Cell (1990) 9.24
Transcription activation by the adenovirus E1a protein. Nature (1989) 9.08
New procedure for DNA transfection with polycation and dimethyl sulfoxide. Mol Cell Biol (1984) 8.63
A vector for expressing GAL4(1-147) fusions in mammalian cells. Nucleic Acids Res (1989) 8.06
The inducible transcription activator NF-kappa B: regulation by distinct protein subunits. Biochim Biophys Acta (1991) 7.70
DNA binding and I kappa B inhibition of the cloned p65 subunit of NF-kappa B, a rel-related polypeptide. Cell (1991) 6.63
Characterization of an immediate-early gene induced in adherent monocytes that encodes I kappa B-like activity. Cell (1991) 6.49
The p65 subunit is responsible for the strong transcription activating potential of NF-kappa B. EMBO J (1991) 6.08
A 65-kappaD subunit of active NF-kappaB is required for inhibition of NF-kappaB by I kappaB. Genes Dev (1989) 5.61
Isolation of a rel-related human cDNA that potentially encodes the 65-kD subunit of NF-kappa B. Science (1991) 5.52
Cloning of an NF-kappa B subunit which stimulates HIV transcription in synergy with p65. Nature (1991) 5.07
The v-rel oncogene encodes a kappa B enhancer binding protein that inhibits NF-kappa B function. Cell (1990) 4.87
Cloning of a mitogen-inducible gene encoding a kappa B DNA-binding protein with homology to the rel oncogene and to cell-cycle motifs. Nature (1990) 4.61
Nucleic acid sequences of the oncogene v-rel in reticuloendotheliosis virus strain T and its cellular homolog, the proto-oncogene c-rel. J Virol (1984) 4.17
RelB, a new Rel family transcription activator that can interact with p50-NF-kappa B. Mol Cell Biol (1992) 4.03
Cloning of the DNA-binding subunit of human nuclear factor kappa B: the level of its mRNA is strongly regulated by phorbol ester or tumor necrosis factor alpha. Proc Natl Acad Sci U S A (1991) 3.80
A common positive trans-acting factor binds to enhancer sequences in the promoters of mouse H-2 and beta 2-microglobulin genes. Proc Natl Acad Sci U S A (1987) 3.80
Rel-associated pp40: an inhibitor of the rel family of transcription factors. Science (1991) 3.76
Transformation by Rous sarcoma virus: a cellular substrate for transformation-specific protein phosphorylation contains phosphotyrosine. Cell (1980) 3.70
Identification of Ets- and notch-related subunits in GA binding protein. Science (1991) 3.69
The rel-associated pp40 protein prevents DNA binding of Rel and NF-kappa B: relationship with I kappa B beta and regulation by phosphorylation. Genes Dev (1991) 3.52
NF-kappa B, KBF1, dorsal, and related matters. Cell (1990) 3.51
NF-kappa B contacts DNA by a heterodimer of the p50 and p65 subunit. EMBO J (1991) 3.28
A DNA-binding protein containing two widely separated zinc finger motifs that recognize the same DNA sequence. Genes Dev (1990) 3.26
Generation of p50 subunit of NF-kappa B by processing of p105 through an ATP-dependent pathway. Nature (1991) 3.26
I kappa B gamma, a 70 kd protein identical to the C-terminal half of p110 NF-kappa B: a new member of the I kappa B family. Cell (1992) 3.25
c-rel activates but v-rel suppresses transcription from kappa B sites. Proc Natl Acad Sci U S A (1991) 2.65
The mouse c-rel protein has an N-terminal regulatory domain and a C-terminal transcriptional transactivation domain. Mol Cell Biol (1990) 2.47
Cytoplasmic retention, DNA binding and processing of the NF-kappa B p50 precursor are controlled by a small region in its C-terminus. EMBO J (1991) 2.39
A large protein containing zinc finger domains binds to related sequence elements in the enhancers of the class I major histocompatibility complex and kappa immunoglobulin genes. Mol Cell Biol (1990) 2.22
Processing of the precursor of NF-kappa B by the HIV-1 protease during acute infection. Nature (1991) 2.18
Oncogenic transformation by vrel requires an amino-terminal activation domain. Mol Cell Biol (1990) 2.15
Inhibition of transcription factors belonging to the rel/NF-kappa B family by a transdominant negative mutant. EMBO J (1991) 2.15
v-rel oncoproteins in the nucleus and in the cytoplasm transform chicken spleen cells. J Virol (1988) 2.08
vRel is an inactive member of the Rel family of transcriptional activating proteins. J Virol (1991) 2.04
Different localization of the product of the v-rel oncogene in chicken fibroblasts and spleen cells correlates with transformation by REV-T. Cell (1986) 1.96
Transactivation of gene expression by nuclear and cytoplasmic rel proteins. Mol Cell Biol (1989) 1.87
Cloning and expression of a chicken c-rel cDNA: unlike p59v-rel, p68c-rel is a cytoplasmic protein in chicken embryo fibroblasts. Oncogene (1990) 1.80
Proteins controlling the nuclear uptake of NF-kappa B, Rel and dorsal. Trends Cell Biol (1991) 1.68
Avian reticuloendotheliosis virus-transformed lymphoid cells contain multiple pp59v-rel complexes. J Virol (1990) 1.57
Malignant transformation by mutant Rel proteins. Trends Genet (1991) 1.41
Viral rel and cellular rel associate with cellular proteins in transformed and normal cells. Oncogene (1989) 1.39
The v-rel and c-rel proteins exist in high molecular weight complexes in avian and murine cells. Oncogene (1991) 1.32
Detection and characterization of the protein encoded by the v-rel oncogene. Virology (1986) 1.30
A protein kinase-A recognition sequence is structurally linked to transformation by p59v-rel and cytoplasmic retention of p68c-rel. Mol Cell Biol (1991) 1.29
Angiotensinogen gene-inducible enhancer-binding protein 1, a member of a new family of large nuclear proteins that recognize nuclear factor kappa B-binding sites through a zinc finger motif. Mol Cell Biol (1991) 1.23
Localization of the v-rel protein in reticuloendotheliosis virus strain T-transformed lymphoid cells. J Virol (1986) 1.16
Detection and characterization of the protein encoded by the chicken c-rel protooncogene. Oncogene Res (1988) 1.14
The v-rel oncogene product is complexed with cellular proteins including its proto-oncogene product and heat shock protein 70. Virology (1990) 1.10
Interaction of the v-rel protein with an NF-kappa B DNA binding site. Proc Natl Acad Sci U S A (1991) 1.04
Alteration of a single nucleotide allows efficient binding of H2TF1/KBF1 to the immunoglobulin kappa enhancer B motif. Mol Cell Biol (1989) 1.00
Repression of the chicken c-rel promoter by vRel in chicken embryo fibroblasts is not mediated through a consensus NF-kappa B binding site. Oncogene (1991) 0.99
Identification of protein complexes containing the c-rel proto-oncogene product in avian hematopoietic cells. Oncogene (1990) 0.94
Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene (1999) 4.76
T-cell co-stimulation through B7RP-1 and ICOS. Nature (1999) 4.20
Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene (2006) 3.49
Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci U S A (2000) 3.37
Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol Cell Biol (1996) 3.22
Human platelet-derived growth factor. Purification and resolution into two active protein fractions. J Biol Chem (1981) 3.21
Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol (1999) 3.21
Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ (2006) 3.04
Platelet factor 4 is chemotactic for neutrophils and monocytes. Proc Natl Acad Sci U S A (1981) 3.03
Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J Biol Chem (1996) 2.85
Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1. J Virol (1995) 2.71
Notch activity influences the alphabeta versus gammadelta T cell lineage decision. Cell (1997) 2.66
Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci U S A (1977) 2.45
An activated form of Notch influences the choice between CD4 and CD8 T cell lineages. Cell (1996) 2.42
The Epstein-Barr virus nuclear protein 2 acidic domain forms a complex with a novel cellular coactivator that can interact with TFIIE. Mol Cell Biol (1995) 2.36
Retroviral envelope glycoproteins contain a "leucine zipper"-like repeat. AIDS Res Hum Retroviruses (1990) 2.24
Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc Natl Acad Sci U S A (1996) 2.18
Oncogenic transformation by vrel requires an amino-terminal activation domain. Mol Cell Biol (1990) 2.15
Evidence for a protective role of pulmonary surfactant protein D (SP-D) against influenza A viruses. J Clin Invest (1994) 2.14
Induction of midbrain dopaminergic neurons by Sonic hedgehog. Neuron (1995) 2.08
Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-kappaB activation. J Virol (1997) 2.05
vRel is an inactive member of the Rel family of transcriptional activating proteins. J Virol (1991) 2.04
Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol (1999) 2.02
Role of the TRAF binding site and NF-kappaB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J Virol (1998) 2.02
Pseudomyxoma peritonei syndrome. Adv Surg (1996) 1.99
Different localization of the product of the v-rel oncogene in chicken fibroblasts and spleen cells correlates with transformation by REV-T. Cell (1986) 1.96
Reconciliation of international administrative coding systems for comparison of colorectal surgery outcome. Colorectal Dis (2014) 1.91
ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms. J Biol Chem (1994) 1.88
Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J Biol Chem (1996) 1.87
CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene (1996) 1.85
Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-kappaB through a pathway that includes the NF-kappaB-inducing kinase and the IkappaB kinases IKKalpha and IKKbeta. Proc Natl Acad Sci U S A (1998) 1.81
Cloning and expression of a chicken c-rel cDNA: unlike p59v-rel, p68c-rel is a cytoplasmic protein in chicken embryo fibroblasts. Oncogene (1990) 1.80
Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology (2000) 1.78
Lymphotoxin-beta receptor signaling complex: role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor kappaB. Proc Natl Acad Sci U S A (1997) 1.76
Epstein-barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-kappaB. Oncogene (1999) 1.69
Genetic and biochemical evidence that EBNA 2 interaction with a 63-kDa cellular GTG-binding protein is essential for B lymphocyte growth transformation by EBV. Virology (1994) 1.69
Effects of cisapride on QT interval in children. J Pediatr (1998) 1.59
Purification and biochemical characterization of CP4 (SP-D), a collagenous surfactant-associated protein. Biochemistry (1989) 1.55
Molecular structure of pulmonary surfactant protein D (SP-D). J Biol Chem (1994) 1.51
Surfactant protein D is a divalent cation-dependent carbohydrate-binding protein. J Biol Chem (1990) 1.51
Drug- and toxin-induced rhabdomyolysis. Ann Emerg Med (1989) 1.51
Surfactant protein-D modulates interaction of Pneumocystis carinii with alveolar macrophages. J Lab Clin Med (1995) 1.49
Interactions of recombinant human pulmonary surfactant protein D and SP-D multimers with influenza A. Am J Physiol (1996) 1.49
Tyrosine phosphorylation of a 50K cellular polypeptide associated with the Rous sarcoma virus transforming protein pp60src. Mol Cell Biol (1982) 1.49
Acute enlargement and subsequent rupture of an abdominal aortic aneurysm in a patient receiving chemotherapy for pancreatic carcinoma. J Vasc Surg (2000) 1.48
Indirect detection of intraoperative carbon monoxide exposure by mass spectrometry during isoflurane anesthesia. Anesthesiology (1995) 1.44
Maternal recall of infant feeding events is accurate. J Epidemiol Community Health (1992) 1.42
Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes (1990) 1.41
Fascin, a sensitive new marker for Reed-Sternberg cells of hodgkin's disease. Evidence for a dendritic or B cell derivation? Am J Pathol (1997) 1.39
The C terminus of the NF-kappa B p50 precursor and an I kappa B isoform contain transcription activation domains. Nucleic Acids Res (1992) 1.36
LIM domain protein Trip6 has a conserved nuclear export signal, nuclear targeting sequences, and multiple transactivation domains. Biochim Biophys Acta (2001) 1.33
Recombinant pulmonary surfactant protein D. Post-translational modification and molecular assembly. J Biol Chem (1994) 1.32
Amino acid sequence of rabbit muscle aldolase and the structure of the active center. Science (1974) 1.32
Surfactant protein D enhances phagocytosis and killing of unencapsulated phase variants of Klebsiella pneumoniae. Infect Immun (2001) 1.30
A protein kinase-A recognition sequence is structurally linked to transformation by p59v-rel and cytoplasmic retention of p68c-rel. Mol Cell Biol (1991) 1.29
Mapping of the active site of recombinant human erythropoietin. Blood (1997) 1.25
Phosphorylation of IkappaB-alpha inhibits its cleavage by caspase CPP32 in vitro. J Biol Chem (1997) 1.25
Detection of platelet-derived growth factor (PDGF)-AA in actively healing human wounds treated with recombinant PDGF-BB and absence of PDGF in chronic nonhealing wounds. J Clin Invest (1995) 1.25
Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway. Oncogene (1999) 1.24
Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg (1998) 1.24
Surfactant protein D interacts with Pneumocystis carinii and mediates organism adherence to alveolar macrophages. J Clin Invest (1995) 1.24
Primary structure of cholera toxin subunit A1: isolation, partial sequences and alignment of the BrCN fragments. FEBS Lett (1979) 1.20
Cloning and characterization of B delta, a novel regulatory subunit of protein phosphatase 2A. FEBS Lett (1999) 1.20
A novel chordin-like protein inhibitor for bone morphogenetic proteins expressed preferentially in mesenchymal cell lineages. Dev Biol (2001) 1.19
Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration. Anticancer Drugs (1996) 1.19
Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features. World J Surg (1999) 1.17
Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery. J Am Coll Surg (1995) 1.15
Comparison of demographic and donation profiles and transfusion-transmissible disease markers and risk rates in previously transfused and nontransfused blood donors. Transfusion (2004) 1.15
Enhanced anti-influenza activity of a surfactant protein D and serum conglutinin fusion protein. Am J Physiol Lung Cell Mol Physiol (2000) 1.15
Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors. Cell Growth Differ (2000) 1.14
The effects of intra-arterial vasoconstrictors on the distribution of a radiolabelled low molecular weight marker in an experimental model of liver tumour. Br J Cancer (1991) 1.14
Site-directed mutagenesis of Cys-15 and Cys-20 of pulmonary surfactant protein D. Expression of a trimeric protein with altered anti-viral properties. J Biol Chem (1996) 1.14
Pleuropulmonary melioidosis in a Cambodian refugee. Can Med Assoc J (1984) 1.12
Interaction of the v-Rel oncoprotein with cellular transcription factor Sp1. J Virol (1994) 1.12
Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer (1996) 1.12
Peritoneal carcinomatosis from adenocarcinoma of the colon. World J Surg (1996) 1.11
CP4: a pneumocyte-derived collagenous surfactant-associated protein. Evidence for heterogeneity of collagenous surfactant proteins. Biochemistry (1988) 1.11
Inhibition of gastric and intestinal motor activity in dogs by (Gln4) neurotensin. Acta Physiol Scand (1977) 1.10
Women's health and social change: the case of lay midwives. Int J Health Serv (1988) 1.10
Effect of donor ethnicity on kidney survival in different recipient pairs: an analysis of the OPTN/UNOS database. Transplant Proc (2009) 1.09
Human surfactant protein D: SP-D contains a C-type lectin carbohydrate recognition domain. Arch Biochem Biophys (1991) 1.09
Complementary DNA cloning of a receptor for tumor necrosis factor and demonstration of a shed form of the receptor. Proc Natl Acad Sci U S A (1990) 1.08
Pancreastatin and islet hormone release. Proc Natl Acad Sci U S A (1987) 1.08
v-Rel and c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence. Oncogene (1993) 1.07
Early recognition of atypical Francisella tularensis strains lacking a cysteine requirement. J Clin Microbiol (1994) 1.07
Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology (1998) 1.06
The v-Rel oncoprotein blocks apoptosis and proteolysis of I kappa B-alpha in transformed chicken spleen cells. Oncogene (1995) 1.06
Vascular endothelial cells and granulopoiesis: interleukin-1 stimulates release of G-CSF and GM-CSF. Blood (1988) 1.06
Metabolic engineering as therapy for inborn errors of metabolism--development of mice with phenylalanine hydroxylase expression in muscle. Gene Ther (1998) 1.05
Thrombolytic therapy: what is its role in free flap salvage? Ann Plast Surg (2001) 1.05
Enhanced antiviral and opsonic activity of a human mannose-binding lectin and surfactant protein D chimera. J Immunol (2000) 1.05
Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg (2000) 1.04
Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer (2004) 1.04
Disulfide bonds stabilize JC virus capsid-like structure by protecting calcium ions from chelation. FEBS Lett (2001) 1.04
Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. Eur J Cancer (1999) 1.04
Impact of surgical and clinical factors on the pharmacology of intraperitoneal doxorubicin in 145 patients with peritoneal carcinomatosis. Eur J Surg Oncol (2011) 1.04
An analysis of errors in kinematic parameters associated with in vivo functional radiographs. Spine (Phila Pa 1976) (1992) 1.03